title: Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms.
abstract: Evidence supporting the combination of aminoglycosides with beta-lactams for gram-negative bacteremia is inconclusive. We have explored the influence on survival of empirical therapy with a beta-lactam alone versus that with a beta-lactam-aminoglycoside combination by retrospectively analyzing a series of bacteremic episodes due to aerobic or facultative gram-negative microorganisms treated with single or combination therapy. The outcome variable was a 30-day mortality. Prognostic factors were selected by regression logistic analysis. A total of 4,863 episodes were assessed, of which 678 (14%) received combination therapy and 467 (10%) were fatal. Factors independently associated with mortality included age greater than 65 (odds ratio [OR], 2; 95% confidence interval [CI], 1.6 to 2.6), hospital acquisition (OR, 1.5; 95% CI, 1.2 to 1.9), a rapidly or ultimately fatal underlying disease (OR, 2.5; 95% CI, 2 to 3.2), cirrhosis (OR, 1.9; 95% CI, 1.4 to 2.6), prior corticosteroids (OR, 1.5; 95% CI, 1.1 to 2), shock on presentation (OR, 8.8; 95% CI, 7 to 11), pneumonia (OR, 2.8; 95% CI, 1.9 to 4), and inappropriate empirical therapy (OR, 1.8; 95% CI, 1.3 to 2.5). Subgroup analysis revealed that combination therapy was an independent protective factor in episodes presenting shock (OR, 0.6; 95% CI, 0.4 to 0.9) or neutropenia (OR, 0.5; 95% CI, 0.3 to 0.9). Combination therapy improved the appropriateness of empirical therapy in episodes due to extended-spectrum beta-lactamase (ESBL)- or AmpC-producing Enterobacteriaceae and Pseudomonas aeruginosa. In patients with gram-negative bacteremia, we could not find an overall association between empirical beta-lactam-aminoglycoside combination therapy and prognosis. However, a survival advantage cannot be discarded for episodes presenting shock or neutropenia, hence in these situations the use of combination therapy may still be justified. Combination therapy also should be considered for patients at risk of being infected with resistant organisms, if only to increase the appropriateness of empirical therapy.
authors.affiliation: Department of Infectious Diseases, Hospital Clinic-IDIBAPS, Villarroel 170, 08036 Barcelona, Spain. jamarti@clinic.ub.es
authors.forename: J A
authors.initials: JA
authors.lastname: Martínez
authors.forename: N
authors.initials: N
authors.lastname: Cobos-Trigueros
authors.forename: A
authors.initials: A
authors.lastname: Soriano
authors.forename: M
authors.initials: M
authors.lastname: Almela
authors.forename: M
authors.initials: M
authors.lastname: Ortega
authors.forename: F
authors.initials: F
authors.lastname: Marco
authors.forename: C
authors.initials: C
authors.lastname: Pitart
authors.forename: H
authors.initials: H
authors.lastname: Sterzik
authors.forename: J
authors.initials: J
authors.lastname: Lopez
authors.forename: J
authors.initials: J
authors.lastname: Mensa
mesh_terms: D000368:Aged; D000617:Aminoglycosides / Q000494:pharmacology / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy* / Q000382:microbiology*; D004755:Enterobacteriaceae / Q000187:drug effects / Q000472:pathogenicity; D005260:Female; D006090:Gram-Negative Bacteria / Q000187:drug effects / Q000472:pathogenicity*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011446:Prospective Studies; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000472:pathogenicity; D047090:beta-Lactams / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000617:Aminoglycosides; D047090:beta-Lactams